MXPA02005626A - Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. - Google Patents
Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente.Info
- Publication number
- MXPA02005626A MXPA02005626A MXPA02005626A MXPA02005626A MXPA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A MX PA02005626 A MXPA02005626 A MX PA02005626A
- Authority
- MX
- Mexico
- Prior art keywords
- osteoporosis
- ductus arteriosus
- compositions
- glomerular filtration
- patent ductus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 230000005856 abnormality Effects 0.000 title 1
- 230000024924 glomerular filtration Effects 0.000 title 1
- 208000003278 patent ductus arteriosus Diseases 0.000 title 1
- 210000003017 ductus arteriosus Anatomy 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000018035 Dental disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 abstract 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 abstract 1
- 208000014151 Stomatognathic disease Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000001605 fetal effect Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Water Treatment By Sorption (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pipe Accessories (AREA)
- Flanged Joints, Insulating Joints, And Other Joints (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45548399A | 1999-12-06 | 1999-12-06 | |
| PCT/CA2000/001445 WO2001042281A1 (en) | 1999-12-06 | 2000-12-06 | Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02005626A true MXPA02005626A (es) | 2004-09-10 |
Family
ID=23808998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02005626A MXPA02005626A (es) | 1999-12-06 | 2000-12-06 | Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7442763B2 (https=) |
| EP (1) | EP1244693B1 (https=) |
| JP (1) | JP2003516417A (https=) |
| AT (1) | ATE298346T1 (https=) |
| AU (1) | AU784630B2 (https=) |
| CA (1) | CA2396739A1 (https=) |
| DE (1) | DE60020997T2 (https=) |
| ES (1) | ES2246915T3 (https=) |
| MX (1) | MXPA02005626A (https=) |
| NZ (1) | NZ520762A (https=) |
| WO (1) | WO2001042281A1 (https=) |
| ZA (1) | ZA200205795B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040235749A1 (en) * | 1999-09-15 | 2004-11-25 | Sylvain Chemtob | G-protein coupled receptor antagonists |
| MXPA02005626A (es) | 1999-12-06 | 2004-09-10 | Pital Sainte Justine H | Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. |
| EP1467738A1 (en) * | 2001-10-08 | 2004-10-20 | Medical Research Council | Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
| JP2005511562A (ja) * | 2001-10-31 | 2005-04-28 | メディカル リサーチ カウンシル | 月経困難症及び月経過多の治療のためのプロスタグランジンレセプターｅｐ２及び／又はｅｐ４のアンタゴニスト |
| CN1662551A (zh) * | 2002-05-23 | 2005-08-31 | 瑟瑞技术公司 | 前列腺素e2受体亚型ep4的拮抗肽 |
| EP1878741A3 (en) * | 2002-05-23 | 2008-02-20 | Theratechnologies Inc. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| US7414029B2 (en) | 2002-05-23 | 2008-08-19 | Theratechnologies, Inc. | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 |
| WO2004073589A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4) |
| US8618054B2 (en) * | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| US20150126573A1 (en) | 2012-05-09 | 2015-05-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019120D0 (en) * | 1990-09-01 | 1990-10-17 | Beecham Group Plc | Novel compounds |
| US5508384A (en) * | 1992-09-10 | 1996-04-16 | New York University | Polypeptide derived from a popamine receptor, and compositions and methods thereof |
| BR9406652A (pt) * | 1993-03-05 | 1996-09-10 | Cytel Corp | Composição |
| US5869281A (en) | 1993-06-25 | 1999-02-09 | Merck Frosst Canada Inc. | DNA encoding prostaglandin receptor FP |
| US5605814A (en) * | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| JPH09504174A (ja) * | 1993-10-29 | 1997-04-28 | インサイト ファーマシューティカルズ，インク． | プロテアーゼネキシン１変異体を含むキメラ蛋白 |
| EP0756604A1 (en) * | 1994-04-22 | 1997-02-05 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Melanoma antigens |
| US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| WO1996006856A1 (en) * | 1994-08-31 | 1996-03-07 | Robert Webber | Dopamine receptor peptides and anti-peptide antibodies |
| WO1996019233A2 (en) * | 1994-12-12 | 1996-06-27 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| JPH11514207A (ja) | 1995-01-25 | 1999-12-07 | シーオーアール・セラピューティックス・インコーポレーテッド | 組換えｃ１４０リセプター、そのアゴニストおよびアンタゴニスト、並びに該リセプターをコードする核酸 |
| US5877155A (en) * | 1995-03-17 | 1999-03-02 | The Research Foundation Of State University Of New York | Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX |
| US6117839A (en) * | 1995-06-07 | 2000-09-12 | Gensci Regeneration Sciences, Inc. | Bone stimulating factor |
| WO1997034621A1 (en) * | 1996-03-21 | 1997-09-25 | Cytel Corporation | Hla-a2.1 binding peptides and their uses |
| JP2001501601A (ja) * | 1996-09-12 | 2001-02-06 | メルク エンド カンパニー インコーポレーテッド | 前立腺ガンの治療において有用な共役体 |
| US5955575A (en) * | 1997-12-22 | 1999-09-21 | Hopital Sainte-Justine | Antagonists of G-protein-coupled receptor |
| AUPP320998A0 (en) * | 1998-04-27 | 1998-05-21 | Walter And Eliza Hall Institute Of Medical Research, The | Tyrosine phosphatase IA-2 T-cell epitopes |
| US6984719B1 (en) * | 1998-09-17 | 2006-01-10 | Hospital Sainte-Justine | Peptide antagonists of prostaglandin F2α receptor |
| US20040235749A1 (en) * | 1999-09-15 | 2004-11-25 | Sylvain Chemtob | G-protein coupled receptor antagonists |
| MXPA02005626A (es) | 1999-12-06 | 2004-09-10 | Pital Sainte Justine H | Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. |
-
2000
- 2000-12-06 MX MXPA02005626A patent/MXPA02005626A/es unknown
- 2000-12-06 EP EP00984691A patent/EP1244693B1/en not_active Expired - Lifetime
- 2000-12-06 CA CA002396739A patent/CA2396739A1/en not_active Abandoned
- 2000-12-06 DE DE60020997T patent/DE60020997T2/de not_active Expired - Fee Related
- 2000-12-06 AT AT00984691T patent/ATE298346T1/de not_active IP Right Cessation
- 2000-12-06 AU AU21340/01A patent/AU784630B2/en not_active Ceased
- 2000-12-06 JP JP2001543578A patent/JP2003516417A/ja not_active Withdrawn
- 2000-12-06 NZ NZ520762A patent/NZ520762A/en active Application Filing
- 2000-12-06 ES ES00984691T patent/ES2246915T3/es not_active Expired - Lifetime
- 2000-12-06 WO PCT/CA2000/001445 patent/WO2001042281A1/en not_active Ceased
-
2002
- 2002-06-04 US US10/162,004 patent/US7442763B2/en not_active Expired - Lifetime
- 2002-07-19 ZA ZA200205795A patent/ZA200205795B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU784630B2 (en) | 2006-05-18 |
| AU2134001A (en) | 2001-06-18 |
| EP1244693A1 (en) | 2002-10-02 |
| NZ520762A (en) | 2005-02-25 |
| US20030017988A1 (en) | 2003-01-23 |
| ATE298346T1 (de) | 2005-07-15 |
| CA2396739A1 (en) | 2001-06-14 |
| DE60020997D1 (de) | 2005-07-28 |
| EP1244693B1 (en) | 2005-06-22 |
| WO2001042281A1 (en) | 2001-06-14 |
| DE60020997T2 (de) | 2006-05-24 |
| ZA200205795B (en) | 2007-01-31 |
| JP2003516417A (ja) | 2003-05-13 |
| ES2246915T3 (es) | 2006-03-01 |
| US7442763B2 (en) | 2008-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02005626A (es) | Composiciones para el tratamiento de filtracion glomerular, conductos arteriosos y osteoporosis del paciente. | |
| KR101956579B1 (ko) | 상아질 지각과민증 완화를 위한 치약 조성물 | |
| BG107697A (en) | Ep4 receptor selective agonists in the treatment of osteoporosis | |
| CA1315480C (en) | Phosphopeptides | |
| AP2001002357A0 (en) | EP4 receptor selective agonists in the treatment of osteoporosis. | |
| PT861261E (pt) | Sequências nucleotídicas e proteicas de genes delta de vertebrado e métodos nelas baseados | |
| EP1484339A3 (en) | Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same | |
| MXPA02006885A (es) | Bloqueo del crecimiento axonal mediado por receptor de nogo. | |
| YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
| DK0664133T3 (da) | "Ostim Apatit"-præparat til stimulering af vækst i knoglevæv | |
| PL329526A1 (en) | Casein peptide containing tooth-cleaning composition of long shelf-life | |
| EP0881908A4 (en) | USE OF FIBROBLAST GROWTH FACTORS FOR STIMULATING BONE GROWTH | |
| EP0950417A3 (en) | Treatment of skeletal disorders | |
| TNSN98104A1 (fr) | Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| ATE469217T1 (de) | Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle | |
| BR112019018871A2 (pt) | complexos para tratar sensibilidade | |
| AU5548801A (en) | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies | |
| AU2003251729A8 (en) | Use of antibodies against flt-1 for the treatment of osteoporosis | |
| IL143956A (en) | Chimeric polypeptide having the antigenic determinants of four proteins of l. infantum, polynucleotides encoding same, methods of production and use thereof in therapeutic compositions | |
| DE60232140D1 (de) | Zusammensetzung zur prävention und/oder behandlung von verändertem knochenmetabolismus | |
| PL353065A1 (en) | Novel polypeptide and dna thereof | |
| Iizuka et al. | Chemical alteration by tooth bleaching of human salivary proteins that infiltrated subsurface enamel lesions—Experimental study with bovine lesion model systems— | |
| NO20016341L (no) | Inhibitorer for integrinet <alfa>v<beta>6 | |
| BR0308040A (pt) | Composições farmacêuticas e cosméticas compreendendo plgf-1 | |
| UA86385C2 (ru) | Композиция зубной пасты, которая содержит растворимое соединение, которое связывает кальций |